SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

moponetug

PRTA·PROTHENA CORP PUBLIC LTD CO
MIXED
Drug Impact Rating7/10
Trial phase
Phase 2
Time to market
If Phase 2 data in 1H 2027 is positive, the program would advance to Phase 3 trials, meaning regulatory approval and commercialization are likely several years away (late 2020s at the earliest).
Why 7/10
The next hard, dated catalyst is the Phase 2 TargetTau-1 topline readout expected in 1H 2027 (roughly 6-8 months from today). This is a binary proof-of-concept readout on Prothena's lead partnered asset, and after the PRX019 termination, moponetug represents a major portion of the company's pipeline value. However, Prothena has other programs (birtamimab, prasinezumab) and the readout is still months away, so the score is 7 rather than 8-9.
Actionable Insight MIXED

The next major catalyst is the Phase 2 TargetTau-1 topline readout expected in 1H 2027. Positive data showing both tau biomarker clearance and cognitive benefit could validate the anti-MTBR tau approach and trigger milestone payments from BMS, while negative or mixed results would severely impair Prothena's pipeline value given the recent PRX019 termination. Watch for BMS's Q4 2026 earnings commentary for any trial timing updates.

Price Chart

Loading chart...

Executive Summary

Moponetug (PRX-005 / BMS-986446) is a Phase 2 anti-tau monoclonal antibody for early Alzheimer's disease, developed by Prothena (PRTA) in partnership with Bristol Myers Squibb. The drug targets the microtubule-binding region of tau protein to clear neurofibrillary tangles. The pivotal TargetTau-1 Phase 2 trial (NCT06268886) is fully enrolled with ~310 patients and topline data is expected in the first half of 2027. Moponetug received FDA Fast Track designation in October 2025. Prothena has received $135 million in licensing payments from BMS to date, with up to $562.5 million in remaining milestones plus tiered royalties. However, on October 28, 2026, BMS terminated a separate collaboration (PRX019), removing up to $617.5 million in potential milestones, though BMS confirmed moponetug's development continues. PRTA trades near its 52-week low around $8.76 with a ~$452M market cap, and a major 10% owner has been aggressively buying shares in recent weeks.

How It Works

Moponetug is an antibody (a type of immune protein) designed to target and help clear tau tangles in the brain. Tau is a protein that, in Alzheimer's disease, forms twisted clumps inside brain cells that disrupt their function. Moponetug binds to a specific region of the tau protein called the microtubule-binding region (MTBR), which is thought to be the part that drives the formation of these toxic tangles. By clearing these tau aggregates, the drug aims to slow or halt cognitive decline in early Alzheimer's patients.

Trial Status

The TargetTau-1 Phase 2 trial (NCT06268886) is a randomized, double-blind, placebo-controlled global study in approximately 310 patients with early Alzheimer's disease. The trial is fully enrolled and active but not recruiting. Primary completion is expected in the first half of 2027. A Phase 1 subcutaneous formulation study was also initiated in August 2026. Phase 1 data showed the drug was well tolerated and achieved CNS concentrations sufficient for pharmacological targeting of MTBR-tau.

The Two-Sided Case

▲ Bull Case5
Moponetug targets tau pathology, a distinct mechanism from approved amyloid-clearing Alzheimer's drugs (Leqembi, Kisunlea), offering a potential combination or second-line approach in a massive market.
FDA Fast Track designation (October 2025) provides regulatory pathway advantages including rolling review and priority review eligibility.
BMS, a top-tier pharma partner, is fully funding development and has already paid $135 million in licensing fees, with up to $562.5 million in remaining milestones plus tiered royalties.
Major 10% owner William P. Scully has purchased over $7 million worth of PRTA shares at ~$8-8.60 in September-October 2026, signaling insider conviction near 52-week lows.
Prothena has a strong cash position of ~$289 million (June 2026) providing runway through the Phase 2 readout and beyond.
▼ Bear Case5
No tau-targeting antibody has been approved for Alzheimer's to date; the biology is unproven and several prior anti-tau antibodies have failed in clinical trials.
The Phase 2 readout is still 6-8 months away (1H 2027), and the stock could drift lower with no near-term catalysts.
BMS recently terminated the PRX019 collaboration (October 28, 2026), removing up to $617.5 million in potential milestones and raising questions about BMS's commitment to the neuroscience partnership.
Analyst coverage is stale (last action May 2026) and the stock trades near its 52-week low of $7.73 with a market cap of only ~$452 million, reflecting low investor conviction.
The Alzheimer's treatment landscape is increasingly crowded with approved amyloid antibodies (Leqembi, Kisunlea) and numerous tau-targeting competitors from Eli Lilly, Roche, Biogen, and others.

Upcoming Catalysts

  • Phase 2 TargetTau-1 topline data readout expected in 1H 2027
  • BMS Q4 2026 earnings call for potential trial timing updates
  • Prothena Q3 2026 earnings report on November 5, 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PROTHENA CORP PUBLIC LTD CO 8-K PRTA ·Originating report

Sources · 12

Hover a chip for the title
1 adisinsight.springer.com2 sec.gov3 ir.prothena.com4 prothena.com5 clinicaltrials.gov6 news.bms.com7 biospace.com8 marketbeat.com9 sec.gov10 alz-journals.onlinelibrary.wiley.com11 dafinchi.ai12 prothena.com